Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesProteomics International Laboratories Ltd

Proteomics International Laboratories Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.098 AUD 0.00 ( 2.08%)
Last update at 2026-11-12T04:08:00Z
VOLUME
108329
Market Cap
16.54M

Momentum Score

…

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes. The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. The company also offers analytical services, such as biomarker discovery and validation, biosimilars/biologics characterisation, and pharmacokinetic testing. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Nedlands, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.10
Low
0.10
High
52 Week Price Range
0.09
Low
0.86
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Proteomics International Laboratories is an Australian diagnostics and life‑sciences company focused on proteomics-based biomarker tests and laboratory research services, with a lead program aimed at predicting diabetic kidney disease progression. Long-term growth drivers include commercialisation and clinical adoption of its prognostic platform, expansion of contract testing and discovery services, and potential licensing or distribution partnerships that may benefit scale and recurring revenue. The company may appeal to investors interested in specialised diagnostic technology with platform potential rather than established earnings.

The primary investment risks are execution and regulatory hurdles to commercialisation, limited operating history and revenue visibility, and the financing and market risks typical of small biotechnology firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.10
Dividend Yield
-
Revenue TTM
3.37M
Revenue Per Share
0.03
Gross Profit TTM
1.89M
Debt / Equity
0.06
ROE
-92.99%
Net Debt
-3.17M
ROCE
-170.18%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -10.78M -8.15M -8.64M -6.23M -4.97M
Minority interest - 0.04M 0.11M - -
Net income -8.56M -8.11M -6.38M -6.23M -4.97M
Selling general administrative - 6.17M 5.55M 5.11M 4.36M
Selling and marketing expenses - - -3.83M - 0.12M
Gross profit -9.07M 0.96M -1.12M -1.62M -0.57M
Reconciled depreciation - 0.62M 0.73M 0.53M 0.42M
Ebit -11.89M -10.62M -9.12M -8.83M -4.97M
Ebitda -11.08M -10.00M -8.40M -8.30M -4.56M
Depreciation and amortization 0.81M 0.62M 0.73M 0.53M 0.42M
Operating income -11.89M -10.62M -9.12M -6.37M -4.98M
Other operating expenses 12.17M 11.58M 10.51M 4.86M 4.29M
Interest expense 0.04M - 0.02M - 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.20M 0.28M 0.14M 0.01M
Net interest income - 0.16M 0.26M 0.14M 0.00M
Income tax expense -2.17M - -2.16M -0.15M 1.94M
Total revenue 0.28M 0.96M 0.89M 0.73M 1.49M
Total operating expenses 2.82M 11.58M 8.49M 9.55M 8.41M
Cost of revenue 9.35M - 2.02M 2.35M 2.06M
Total other income expense net 1.10M 2.46M 0.49M 2.45M 1.94M
Net income from continuing ops - -8.15M -6.48M -6.23M -4.97M
Net income applicable to common shares - -8.11M -6.38M -6.18M -4.97M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 8.88M 14.78M 10.88M 10.08M 5.40M
Intangible assets 0.00M 0.00M 0.00M 0.00M 0.00M
Other current assets 0.06M 2.24M 0.12M 1.97M 1.73M
Total liab 3.33M 1.81M 1.63M 1.75M 2.00M
Total stockholder equity 5.81M 13.17M 9.41M 8.38M 3.39M
Other current liab 0.73M 1.12M 0.50M 0.55M 1.18M
Common stock 48.32M 47.64M 36.81M 30.18M 19.34M
Capital stock - 47.64M 36.81M 30.18M 19.34M
Retained earnings -45.41M -37.79M -29.67M -23.63M -17.63M
Other liab - - - - 0.30M
Other assets - - 0.00M 0.06M 0.06M
Cash 3.50M 11.04M 6.64M 6.03M 2.11M
Cash and equivalents - - - 5.79M 1.00M
Total current liabilities 1.90M 1.44M 0.90M 1.10M 1.70M
Current deferred revenue 0.86M 0.17M 0.25M 0.37M 0.36M
Net debt -3.17M -10.76M -6.32M -5.96M -2.11M
Short term debt 0.20M 0.15M 0.10M 0.03M -0.36M
Short long term debt total 0.33M 0.28M 0.32M 0.06M 0.06M
Other stockholder equity - - - -6.55M -1.71M
Property plant equipment - - - 1.69M 0.97M
Total current assets 6.05M 13.52M 9.16M 8.33M 4.36M
Net tangible assets - - - - 3.39M
Net receivables 2.49M 0.24M 2.41M 0.21M 0.44M
Inventory - - - 0.12M 0.08M
Accounts payable 0.11M - 0.06M 0.15M 0.52M
Accumulated other comprehensive income 2.89M 3.32M 2.27M 1.83M 1.68M
Non currrent assets other - - -0.00M 0.06M 0.06M
Non current assets total 2.84M 1.26M 1.71M 1.75M 1.03M
Capital lease obligations - 0.28M 0.32M 0.06M -
Long term debt total - - - 0.03M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.03M -0.39M -1.17M -0.13M
Change to liabilities - - - 0.00M 1.01M
Total cashflows from investing activities -2.01M -0.03M -0.39M -1.17M -0.13M
Net borrowings - - - - -0.07M
Total cash from financing activities 0.35M 11.03M 6.59M 10.77M 0.18M
Change to operating activities - - - - -0.36M
Net income -8.56M -8.11M -6.38M -6.18M -4.97M
Change in cash -7.54M 4.40M 0.61M 3.92M -3.49M
Begin period cash flow 11.04M 6.64M 6.03M 2.11M 5.60M
End period cash flow 3.50M 11.04M 6.64M 6.03M 2.11M
Total cash from operating activities -5.87M -6.60M -5.59M -5.69M -3.54M
Issuance of capital stock - 11.20M 6.63M 10.84M 0.25M
Depreciation 0.81M - 0.73M 0.53M 0.42M
Other cashflows from investing activities - 0.00M 0.02M 0.05M 0.00M
Change to inventory - - - 0.66M -0.64M
Change to account receivables -0.20M - -0.04M 0.29M -0.14M
Sale purchase of stock - 11.20M 6.63M 10.84M 0.25M
Other cashflows from financing activities -0.34M -0.17M -0.04M -0.07M -0.31M
Change to netincome - - - 0.32M 0.51M
Capital expenditures 2.01M 0.03M 0.40M 1.22M 0.13M
Change in working capital 1.41M 0.23M -0.67M 0.29M -0.14M
Stock based compensation - - 0.78M 0.32M 0.51M
Other non cash items 0.47M -6.60M 0.72M -0.05M 1.02M
Free cash flow -7.88M -6.63M -6.00M -6.91M -3.67M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PIQ
Proteomics International Laboratories Ltd		 0.00
2.08%		 0.10 - - 4.91 2.79 46.90 -19.48
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes. The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. The company also offers analytical services, such as biomarker discovery and validation, biosimilars/biologics characterisation, and pharmacokinetic testing. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Nedlands, Australia.

Harry Perkins Institute of Medical Research, Nedlands, WA, Australia, 6009

61 8 9389 1992

https://www.proteomics.com.au

Name Title Year Born
Dr. Richard John Lipscombe M.A., MA (Oxford), Ph.D., Ph.D., (London) Co-Founder, MD & Director NA
Ms. Jacqueline Gray Chief Financial Officer NA
Mr. Vikesh Malik Chief Commercialisation Officer NA
Mr. John Chuck Morrison Head of Bus. Devel. NA
Dr. Scott Bringans Head of Research NA
Dr. Pearl Tan Head of Logistics NA
Dr. Kirsten Peters Head of Clinical Studies NA
Ms. Karen Teresa Logan B.Com., FCIS, BCom, DipAppCorpGov, FFin, ACIS, AGI Company Sec. NA
Mr. John Chuck Morrison Head of Business Development NA
Ms. Karen Teresa Logan ACIS, B.Com., BCom, DipAppCorpGov, F Fin, FCIS, FC Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…